Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity (Tables)

Equity (Tables)

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

Schedule of summary of stock option activity

						Options Outstanding
		Shares Available												Weighted Average
		for Grant of				Number of								Exercise
		Options				Shares				Price per Share				Price
Balance at December 31, 2013			0				0			NA				NA
Approval of authorized shares			3,200,000
Options granted			(1,730,000	)			1,730,000			$	0.42			$	0.42
Options exercised			0				0
Options cancelled			0				0
Balance at December 31, 2014			1,470,000				1,730,000			$	0.42			$	0.42
Options granted			(80,000	)			80,000			$	3.00			$	3.00
Options exercised			0				0
Options cancelled			0				0
Balance at June 30, 2015			1,390,000				1,810,000			$	0.53			$	0.53

Schedule of weighted average assumptions for employee options

	For the Six Months Ended June 30,
	2015		2014
Dividend yield	0.00%		NA
Volatility factor	75.00%		NA
Risk-free interest rate	1.85%		NA
Expected term (years)	6.5		NA
Weighted-average fair value of options granted during the periods	$2.13		NA